4.7 Article

Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae

期刊

EMERGING MICROBES & INFECTIONS
卷 10, 期 1, 页码 2042-2051

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2021.1984182

关键词

Ceftazidime-avibactam; KPC; LamB; PBP3; expression level of bla (KPC)

资金

  1. National Natural Science Foundation of China [81861138056]
  2. Guangzhou Municipal Science and Technology Bureau [201607020044]

向作者/读者索取更多资源

This study identified a novel mechanism of CAZ-AVI resistance associated with mutations in the porin LamB in KPC-Kp strains.
Ceftazidime-avibactam (CAZ-AVI) shows promising activity against carbapenem-resistant Klebsiella pneumoniae (CRKP), however, CAZ-AVI resistance have emerged recently. Mutations in KPCs, porins OmpK35 and/or OmpK36, and PBPs are known to contribute to the resistance to CAZ-AVI in CRKP. To identify novel CAZ-AVI resistance mechanism, we generated 10 CAZ-AVI-resistant strains from 14 CAZ-AVI susceptible KPC-producing K. pneumoniae (KPC-Kp) strains through in vitro multipassage resistance selection using low concentrations of CAZ-AVI. Comparative genomic analysis for the original and derived mutants identified CAZ-AVI resistance-associated mutations in KPCs, PBP3 (encoded by ftsI), and LamB, an outer membrane maltoporin. CAZ-AVI susceptible KPC-Kp strains became resistant when complemented with mutated bla (KPC) genes. Complementation experiments also showed that a plasmid borne copy of wild-type lamB or ftsI gene reduced the MIC value of CAZ-AVI in the induced resistant strains. In addition, bla (KPC) expression level increased in four of the six CAZ-AVI-resistant strains without KPC mutations, indicating a probable association between increased bla (KPC) expression and increased resistance in these strains. In conclusion, we here identified a novel mechanism of CAZ-AVI resistance associated with mutations in porin LamB in KPC-Kp.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据